Lantern Pharma Announces Positive Preclinical Data in Glioblastoma (GBM) with Drug Candidate LP-184 and Expands GBM Research Collaboration

- LP-184 treatment induced tumor regression evidenced by over 106% tumor growth inhibition - LP-184 reduced xenograft tumor volume in mice by greater than 85% within the treatment group - LP-184 resulted in a statistically significant (p < 0.0001) extension of median overall survival compared to the control group - Lantern extends R&D collaboration with Johns Hopkins University into next phase with focus on areas of high patient need in GBM

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here